Search

Akkermansia muciniphila (AKK) is a gut probiotic with great potential. It was only discovered in 2004 and has unique growth requirements. Therefore, comparing to other probiotics, AKK still needs to be explored. To understand the research status and development of AKK, the related literatures of AKK were excavated and sorted out. AKK is associated with metabolic and immune diseases. The current mainstream research is obesity and type 2 diabetes. In addition, AKK can also have a positive impact on autoimmune diseases, cancer, intestinal diseases, liver diseases, cardiovascular diseases, nervous system diseases, aging, periodontitis, and allergies. However, AKK may aggravate the development of diseases in some specific environments. People pay more and more attention to the influence of diet and drugs on the active AKK, and even put forward treatment programs such as pasteurized AKK (PAKK), AKK outer membrane protein Amuc_1100, and external vesicles, which greatly improves the security of AKK use. In the future, in addition to the treatment of diseases, the focus of AKK research will be expanded to areas such as safety assessment and optimization of cultivation conditions. [ABSTRACT FROM AUTHOR]